PATHOPHYSIOLOGY • CARDIOVASCULAR PATHOPHYSIOLOGY

Tachyarrhythmia vs. Bradyarrhythmia

Understanding how abnormal heart rates arise and threaten hemodynamic stability.

Historical Context & Motivation

The recognition that the heart could beat too quickly or too slowly predates modern medicine, but the ability to systematically classify and treat these disorders emerged only with the advent of electrocardiography in the early twentieth century. Before Willem Einthoven's string galvanometer, clinicians relied on pulse palpation and auscultation—crude tools that could detect gross rate abnormalities but offered no insight into the underlying electrical mechanism. The development of continuous cardiac monitoring transformed arrhythmia science from bedside guesswork into a precise discipline grounded in electrophysiology. Today, the distinction between tachyarrhythmias and bradyarrhythmias remains a foundational concept in cardiovascular pathophysiology, guiding acute management decisions in emergency departments and critical care units worldwide.

1887
First Human Electrocardiogram
Augustus Waller records the first human electrocardiogram using a capillary electrometer, demonstrating that the heart's electrical activity could be measured from the body surface.
1903
Einthoven's String Galvanometer
Willem Einthoven develops the string galvanometer, producing high-fidelity ECG tracings that allow systematic identification of atrial fibrillation, heart block, and ventricular tachycardia for the first time.
1947
Defibrillation in Humans
Claude Beck successfully defibrillates a human heart during cardiac surgery, proving that lethal tachyarrhythmias like ventricular fibrillation could be electrically terminated.
1958
First Implantable Pacemaker
Åke Senning implants the first pacemaker designed by Rune Elmqvist, revolutionizing the treatment of symptomatic bradyarrhythmias such as complete heart block.
1980s–Present
Catheter Ablation & ICDs
Catheter-based radiofrequency ablation and implantable cardioverter-defibrillators (ICDs) emerge, offering curative and preventive strategies for both tachyarrhythmias and bradyarrhythmias.

The central question that cardiovascular pathophysiology seeks to answer regarding arrhythmias is deceptively simple: why does the heart deviate from its normal rate and rhythm, and what hemodynamic consequences follow? To address this, one must understand the electrical conduction system, the cellular mechanisms of automaticity, and the ways in which structural or metabolic disease disrupts normal impulse generation and propagation.

Core Principles & Definitions

A normal adult resting heart rate falls between 60 and 100 beats per minute (bpm), a range maintained by the sinoatrial (SA) node acting as the dominant pacemaker. When the ventricular rate exceeds 100 bpm, the rhythm is classified as a tachyarrhythmia; when it falls below 60 bpm, it is termed a bradyarrhythmia. These broad categories encompass diverse pathologic entities with distinct etiologies, electrophysiologic substrates, and clinical implications. A clear grasp of their foundational principles is essential before exploring specific subtypes.

1

Automaticity

The intrinsic ability of cardiac pacemaker cells to spontaneously depolarize during diastole. Enhanced automaticity (faster phase-4 depolarization) drives many tachyarrhythmias; depressed automaticity underlies sinus bradycardia.
2

Re-entry

A self-sustaining circuit in which an electrical impulse continuously loops through tissue with unidirectional block and slowed conduction. Re-entry is the most common mechanism underlying sustained tachyarrhythmias such as AVNRT and ventricular tachycardia.
3

Triggered Activity

Abnormal depolarizations—early afterdepolarizations (EADs) or delayed afterdepolarizations (DADs)—that trigger extra beats. EADs are associated with long QT syndrome, while DADs occur with intracellular calcium overload (e.g., digitalis toxicity).
4

Conduction Block

Failure of impulse propagation through the AV node or His-Purkinje system. Degrees of block (first, second, third) produce progressively severe bradyarrhythmias, with complete (third-degree) block requiring an escape pacemaker to sustain life.
KEY TAKEAWAY
Think of the heart's conduction system like a highway network. Tachyarrhythmias are analogous to traffic endlessly circling a roundabout (re-entry) or cars entering the highway too frequently (enhanced automaticity). Bradyarrhythmias resemble a roadblock on the main highway (conduction block) or a traffic light that changes too slowly (depressed automaticity). The clinical consequence in both cases is a disruption of normal flow—in this case, cardiac output.

Visual Explanation — Cardiac Conduction & Rate Deviation

The diagram illustrates the cardiac conduction pathway from the SA node through the AV node, Bundle of His, bundle branches, and Purkinje fibers, alongside the intrinsic firing rates of each pacemaker site. The right panels highlight the mechanisms that accelerate (tachyarrhythmia) or slow (bradyarrhythmia) the heart rate.

The diagram above emphasizes a critical principle: the SA node normally suppresses all subsidiary pacemakers through a mechanism called overdrive suppression. When the SA node fires at 60–100 bpm, slower pacemaker cells in the AV node (40–60 bpm) and Purkinje fibers (20–40 bpm) are reset before they can reach threshold. Tachyarrhythmias arise when ectopic foci exceed the SA node's rate, when re-entry circuits generate self-sustaining loops, or when triggered activity produces premature depolarizations. Bradyarrhythmias develop when the SA node's firing rate declines (as in sick sinus syndrome) or when impulses are delayed or blocked at the AV node or below. In third-degree AV block, the atria and ventricles beat independently, and the ventricular rate depends entirely on the escape pacemaker—often the Purkinje network at a dangerously slow 20–40 bpm.

Hemodynamic Consequences & Quantitative Relationships

The hemodynamic significance of any arrhythmia ultimately depends on its effect on cardiac output (CO), the volume of blood ejected by the heart per minute. Cardiac output is the product of heart rate and stroke volume, and deviations in either direction—too fast or too slow—can compromise tissue perfusion. Understanding these quantitative relationships clarifies why both tachyarrhythmias and bradyarrhythmias can be life-threatening despite representing opposite extremes of rate.

CARDIAC OUTPUT
CO = HR × SV
Where CO = cardiac output (L/min), HR = heart rate (beats/min), SV = stroke volume (mL/beat). Normal CO ≈ 4–8 L/min.

In tachyarrhythmias, the elevated heart rate initially increases cardiac output. However, diastole—the phase during which the ventricles fill with blood and the coronary arteries receive perfusion—shortens disproportionately as rate increases. At very high rates (>150 bpm), diastolic filling time becomes so brief that stroke volume drops precipitously, often outweighing the benefit of the faster rate. The myocardium simultaneously faces increased oxygen demand and decreased coronary perfusion, creating a supply-demand mismatch that can precipitate ischemia, especially in patients with pre-existing coronary artery disease.

RATE-PRESSURE PRODUCT (MYOCARDIAL OXYGEN DEMAND)
RPP = HR × SBP
Where RPP = rate-pressure product (an estimate of myocardial oxygen demand), SBP = systolic blood pressure (mmHg). An RPP > 12,000 suggests increased risk of myocardial ischemia.

In bradyarrhythmias, the pathophysiology is more straightforward: a reduced heart rate directly lowers cardiac output when compensatory increases in stroke volume are insufficient. While healthy individuals (particularly athletes) may tolerate resting rates of 40–50 bpm through enhanced vagal tone and increased stroke volume, pathological bradycardia in the setting of a stiff, noncompliant ventricle—as seen in elderly patients with diastolic dysfunction—produces symptomatic hypoperfusion. End-organ effects include syncope, fatigue, cognitive impairment, and in severe cases, cardiogenic shock.

MEAN ARTERIAL PRESSURE
MAP = CO × SVR
Where MAP = mean arterial pressure (mmHg), SVR = systemic vascular resistance (dyn·s/cm⁵). A fall in CO from either extreme tachycardia or bradycardia lowers MAP and compromises organ perfusion.

Classification of Tachyarrhythmias & Bradyarrhythmias

Both tachyarrhythmias and bradyarrhythmias encompass numerous subtypes that differ in anatomical origin, electrophysiologic mechanism, ECG morphology, and clinical urgency. The most clinically useful classification scheme divides tachyarrhythmias by origin—supraventricular (above the bifurcation of the His bundle) versus ventricular (below the bifurcation)—and bradyarrhythmias by the site of dysfunction—sinus node versus atrioventricular conduction system.

Classification tree showing tachyarrhythmias divided into supraventricular (atrial fibrillation, flutter, AVNRT/AVRT) and ventricular (VT, VF) subtypes, and bradyarrhythmias divided into sinus node dysfunction and AV conduction block subtypes.
Comparative summary of tachyarrhythmias and bradyarrhythmias across clinical dimensions.
FeatureTachyarrhythmiaBradyarrhythmia
Heart Rate> 100 bpm< 60 bpm
MechanismsEnhanced automaticity, re-entry, triggered activityDepressed automaticity, conduction block
Common CausesIschemia, electrolyte imbalance, stimulants, structural heart disease, hyperthyroidismAging/fibrosis of conduction system, hypothyroidism, drugs (β-blockers, CCBs, digoxin), increased vagal tone
Hemodynamic Effect↓ Diastolic filling → ↓ SV → ↓ CO; ↑ myocardial O₂ demand↓ HR directly → ↓ CO if SV cannot compensate
SymptomsPalpitations, chest pain, dyspnea, syncope, sudden cardiac deathFatigue, dizziness, syncope, exercise intolerance, heart failure
Acute TreatmentVagal maneuvers, adenosine, antiarrhythmics, cardioversion/defibrillationAtropine, transcutaneous pacing, dopamine/epinephrine infusion
Definitive TherapyCatheter ablation, ICD implantation, chronic antiarrhythmic drugsPermanent pacemaker implantation, medication adjustment

Worked Example — Clinical Case Analysis

A 72-year-old male presents to the emergency department with a two-day history of progressive lightheadedness, fatigue, and a near-syncopal episode while rising from a chair. His medications include metoprolol 100 mg twice daily for hypertension. Vitals: HR 38 bpm, BP 88/56 mmHg, RR 18, SpO₂ 96% on room air. ECG shows regular P waves at 80/min, regular QRS complexes at 38/min, no consistent relationship between P waves and QRS complexes. Let us systematically work through this case.

Clinical Case: Symptomatic Bradyarrhythmia
1
Step 1 — Identify the Rate DisturbanceThe ventricular rate is 38 bpm, which is well below the normal range of 60–100 bpm. This immediately classifies the rhythm as a bradyarrhythmia. The atrial rate (P wave rate) is 80/min, which is normal.
Classification: Bradyarrhythmia (ventricular rate 38 bpm)
2
Step 2 — Determine the MechanismThe key ECG finding is AV dissociation: P waves march at their own rate (80/min) and QRS complexes march at a slower, independent rate (38/min), with no fixed P-to-QRS relationship. This pattern defines third-degree (complete) AV block. No atrial impulses are conducted to the ventricles; an escape pacemaker (likely junctional or ventricular) sustains ventricular depolarization.
Mechanism: Complete AV conduction block with junctional/ventricular escape rhythm
3
Step 3 — Assess Hemodynamic ImpactUsing the cardiac output equation (CO = HR × SV): assuming a stroke volume of approximately 65 mL, CO = 38 × 0.065 L = 2.47 L/min. Normal resting CO is approximately 5 L/min, so this patient's cardiac output is roughly 50% of normal. The hypotension (88/56 mmHg) and near-syncope directly reflect this hemodynamic compromise.
Estimated CO ≈ 2.5 L/min (dangerously low), confirming hemodynamic instability
4
Step 4 — Identify Contributing FactorsThis patient is taking metoprolol, a beta-adrenergic blocker that slows conduction through the AV node and suppresses automaticity. In the elderly, age-related fibrosis of the conduction system may already compromise AV conduction; the addition of a rate-slowing medication may unmask or exacerbate latent conduction disease. Hypothyroidism, hyperkalemia, and inferior myocardial infarction should also be excluded as contributing etiologies.
Key contributor: Beta-blocker therapy superimposed on age-related conduction system degeneration
5
Step 5 — Determine ManagementFollowing ACLS guidelines for symptomatic bradycardia: (1) administer atropine 0.5 mg IV (may be less effective in infranodal block); (2) if unresponsive, initiate transcutaneous pacing; (3) hold metoprolol; (4) consult cardiology for consideration of temporary transvenous pacing and, if the block persists after medication withdrawal, permanent pacemaker implantation.
Acute: atropine → transcutaneous pacing. Definitive: likely permanent pacemaker

Diagnostic & Therapeutic Comparisons

While the clinical presentations of tachyarrhythmias and bradyarrhythmias overlap significantly—both can cause syncope, hypotension, and heart failure—their diagnostic workup and therapeutic approach differ in critical ways. Recognizing these distinctions is essential for healthcare providers navigating acute management algorithms such as ACLS.

Diagnostic and therapeutic approach comparison for tachyarrhythmias vs. bradyarrhythmias.
DomainTachyarrhythmia ApproachBradyarrhythmia Approach
12-Lead ECG PriorityQRS width (narrow vs. wide) to differentiate SVT from VT; regularity to distinguish flutter/fibrillationP-QRS relationship to determine level of block; escape rhythm morphology to localize site
First-Line DrugAdenosine (for regular narrow-complex SVT); amiodarone (for wide-complex/VT)Atropine 0.5 mg IV (effective primarily for nodal-level block)
Electrical TherapySynchronized cardioversion (unstable SVT/VT); defibrillation (VF/pulseless VT)Transcutaneous pacing → transvenous pacing if pharmacotherapy fails
Device TherapyICD for secondary prevention of VT/VF; catheter ablation for SVT and some VT circuitsPermanent pacemaker (single-chamber or dual-chamber depending on indication)
Reversible CausesHypokalemia, hypomagnesemia, hyperthyroidism, stimulants, PEHypothyroidism, hyperkalemia, drug toxicity (β-blockers, CCBs, digoxin), hypothermia
KEY TAKEAWAY
The ACLS algorithms serve as clinical decision trees: for tachyarrhythmias, the first branch point is hemodynamic stability (stable → pharmacotherapy vs. unstable → immediate cardioversion). For bradyarrhythmias, the critical question is whether symptoms are present. An asymptomatic heart rate of 45 bpm in a conditioned athlete requires no intervention, whereas the same rate in a patient with altered mental status demands immediate action. Context transforms a number into a diagnosis.

Connection to Advanced Electrophysiology & Emerging Therapies

The concepts presented in this lesson form the foundation for more advanced electrophysiology studies encountered in cardiology training. Modern electrophysiology (EP) studies use intracardiac catheters to map the precise location and mechanism of arrhythmias, enabling targeted catheter ablation with radiofrequency or cryothermal energy. Three-dimensional electroanatomic mapping systems (CARTO, EnSite) can visualize scar-related re-entry circuits in patients with ventricular tachycardia post-myocardial infarction, while leadless pacemakers and conduction system pacing (His-bundle pacing, left-bundle branch area pacing) represent the cutting edge of bradyarrhythmia management.

Progression from foundational arrhythmia concepts to advanced electrophysiology.
ConceptFoundational Level (This Lesson)Advanced Electrophysiology
Tachyarrhythmia Diagnosis12-lead ECG: narrow vs. wide QRS, regular vs. irregularIntracardiac electrograms, programmed stimulation, entrainment mapping
Re-entry MechanismConceptual model: unidirectional block + slow conduction3D electroanatomic mapping of voltage channels, identification of critical isthmus for ablation
Bradyarrhythmia TreatmentAtropine, transcutaneous pacing, traditional pacemakerLeadless pacemakers, His-bundle/LBBAP pacing, biological pacemakers (gene therapy—investigational)
Risk StratificationClinical symptoms, hemodynamic stabilityGenetic testing (channelopathies), cardiac MRI for scar characterization, AI-based ECG risk prediction

Looking forward, the field is increasingly incorporating genetic and molecular insights into arrhythmia management. Channelopathies—inherited disorders of ion channel function such as Long QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia—represent a bridge between molecular biology and clinical arrhythmia. Gene therapy approaches, including biological pacemakers that convert working myocardial cells into pacemaker cells through TBX18 gene delivery, remain experimental but illustrate how rapidly this field is evolving.

Practice Problems

PROBLEM 1CONCEPTUAL
A patient has a heart rate of 160 bpm with a narrow QRS complex on ECG. Is this rhythm classified as a tachyarrhythmia or bradyarrhythmia? Based on the QRS width, is the origin more likely supraventricular or ventricular? Explain the physiologic significance of this distinction.
PROBLEM 2BASIC CALCULATION
A patient in complete heart block has a ventricular escape rate of 35 bpm. Assuming a stroke volume of 70 mL, calculate the cardiac output. Compare this to a normal cardiac output of 5 L/min and state the percentage reduction.
PROBLEM 3INTERMEDIATE
A 55-year-old woman presents with palpitations and a heart rate of 150 bpm. Her 12-lead ECG shows a regular, narrow-complex tachycardia with no visible P waves. The resident administers adenosine 6 mg IV push, and the rhythm abruptly terminates, revealing normal sinus rhythm. What is the most likely diagnosis, what mechanism underlies this arrhythmia, and why did adenosine terminate it?
PROBLEM 4APPLIED
A 78-year-old man on diltiazem and digoxin for rate-controlled atrial fibrillation is brought to the ED after a fall. His heart rate is 34 bpm, BP is 78/50 mmHg, and he is confused. ECG shows atrial fibrillation with a slow, regular ventricular response (suggesting a junctional escape rhythm). Outline your step-by-step acute management, explaining why each intervention is chosen and what the likely definitive therapy will be.
PROBLEM 5CRITICAL THINKING
Explain how a single patient could exhibit both tachyarrhythmia and bradyarrhythmia. Describe the pathophysiology of tachy-brady syndrome, identify the underlying disorder it is associated with, and discuss why this coexistence complicates pharmacologic management.

Lesson Summary

Cardiac arrhythmias are broadly divided into tachyarrhythmias (heart rate > 100 bpm) and bradyarrhythmias (heart rate < 60 bpm). Tachyarrhythmias arise through three primary mechanisms—enhanced automaticity, re-entry, and triggered activity—and are further classified as supraventricular (narrow QRS) or ventricular (wide QRS). Bradyarrhythmias result from depressed automaticity of the SA node or conduction block at the AV node or His-Purkinje system, with third-degree block representing the most severe form.

Both extremes compromise cardiac output (CO = HR × SV): tachyarrhythmias reduce diastolic filling time and increase myocardial oxygen demand, while bradyarrhythmias directly lower CO through insufficient heart rate. Acute management of unstable tachyarrhythmias centers on cardioversion or defibrillation, whereas symptomatic bradyarrhythmias require atropine and transcutaneous pacing. Definitive therapies include catheter ablation and ICDs for tachyarrhythmias and permanent pacemakers for bradyarrhythmias. The syndrome of tachy-brady syndrome illustrates that these categories are not mutually exclusive and that individualized management integrating both pharmacological and device-based strategies is often required.

Varsity Tutors • Pathophysiology • Tachyarrhythmia vs. Bradyarrhythmia